Stay updated on Pembrolizumab+Ferumoxytol MRI in NSCLC Brain Metastases Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Ferumoxytol MRI in NSCLC Brain Metastases Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Ferumoxytol MRI in NSCLC Brain Metastases Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update in the study details related to the evaluation of the usefulness of ferumoxytol steady state magnetic resonance imaging technique for response assessment after pembrolizumab and radiation therapy in non-small cell lung cancer with brain metastases.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:55.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a more detailed description, now stating 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.'
    Difference
    47%
    Check dated 2024-05-22T21:10:54.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T21:54:54.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Ferumoxytol MRI in NSCLC Brain Metastases Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Ferumoxytol MRI in NSCLC Brain Metastases Clinical Trial page.